Lung cancer combo trial halted early – what we know

NCT ID NCT05860296

Terminated Disease control Sponsor: SignalChem Lifesciences Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new pill (SLC-391) combined with an immunotherapy drug (pembrolizumab) in 36 adults with advanced non-small cell lung cancer that had spread. The goal was to find a safe dose and see if the combination could shrink tumors. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm metastatic malignant neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER METASTATIC LUNG CANCER STAGE IV LUNG CANCER, NONSMALL CELL

Contacts and locations

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States
Community Health Network

Indianapolis, Indiana, 46250, United States
Cross Cancer Institute

Edmonton, Alberta, Canada
Horizon Verdi Oncology

Lafayette, Indiana, 47905, United States
Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
Juravinski Cancer Centre

Hamilton, Ontario, Canada
Karmanos Cancer Center

Detroit, Michigan, 48201, United States
London Regional Cancer Centre

London, Ontario, Canada
McGill University Health Centre

Montreal, Quebec, H4A 3J1, Canada
Nebraska Cancer Specialists

Omaha, Nebraska, 68130, United States
Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States
Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.